AmerisourceBergen’s Xcenda acquires Dymaxium

VALLEY FORGE, Pa.–(BUSINESS WIRE)–Xcenda,
a part of AmerisourceBergen, today announced the acquisition of
Dymaxium, a trusted market access partner specializing in the exchange
of evidence and information between payers and life science companies
through its FormularyDecisions.com® platform. This acquisition will
further simplify and streamline the necessary communication of clinical
evidence and health economic information between manufacturers and
population health decision makers.

Over the past decade, Dymaxium built FormularyDecisions.com for payers
to provide them efficient access to clinical evidence and economic
product information critical to their assessment of products for
formulary evaluations. Information is provided by subscribing
manufacturers and amassed across multiple independent third-party data
sources. Payers use this information along with other platform tools to
assess value throughout a product’s lifecycle (pre-, peri- and
post-approval) and to aid in evidence-based reimbursement decision
making. The FormularyDecisions.com platform, home to the AMCP (Academy
of Managed Care Pharmacy) eDossier System, allows for the bi-directional
exchange of information, more frequently and effectively, through
ongoing feedback channels for insights on the information most valuable
to payer decision makers.

“Xcenda was founded on the principle of generating credible and
practical health economics and outcomes research for stakeholders to
make informed healthcare decisions that consider the clinical, economic,
and humanistic outcomes of a product,” said Dr. Kristine Flemister,
President of Xcenda. “We are constantly searching for innovative
offerings that make this exchange of information between pharma and
payers simpler and more efficient. We are thrilled to make this a
reality through this acquisition with Dymaxium’s FormularyDecisions.com
and the AMCP eDossier System.”

“With over 2100 registered US payers and healthcare decision makers and
2,300+ FDA approved plus 225+ pre-approval products, Dymaxium’s platform
uniquely supports the exchange of information between payers and life
science organizations to drive value-based reimbursement decisions,”
said Allen Lising, Managing Director of Dymaxium. “We are excited about
combining our technology platform offerings and US payer community with
Xcenda’s leading global market access and health economics expertise.
This partnership accelerates the delivery of our vision to make early
and ongoing exchange of credible product value information between
payers and manufacturers a reality. We look forward to being able to
deliver more information on pipeline and approved products to payers and
providing actionable insights to manufacturers on the information and
value needs of payers.”